The Inflation Reduction Act and Ibrutinib

The Centers for Medicare & Medicaid Services (CMS) announced a 38% reduction in the price of ibrutinib, effective January 2026, following negotiations tied to the Inflation Reduction Act. This marks a significant development as the CMS begins negotiating prices for drugs, aiming to lower costs for Medicare beneficiaries. Various factors influenced this price determination, including the drug's market history and comparative effectiveness against newer therapies, amidst concerns over access, innovation, and industry profitability.